Jonathan A. Epstein

Jonathan A. Epstein

Auto-generated profile, based on publicly available information

Jonathan A. Epstein

Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2022 in Science
Verified
Journal Article
Closed access
JRJoel G. Rurik
Joel G. Rurik
ITIstván Tombácz
István Tombácz
AYAmir Yadegari
Amir Yadegari
PFPedro O. Méndez Fernández
Pedro O. Méndez Fernández
SSSwapnil V. Shewale
Swapnil V. Shewale
JEJonathan A. Epstein
Jonathan A. Epstein
Making CAR T cells in vivo: Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK

11 September 2019 in Nature
Verified
Journal Article
Closed access
PDF file
HAHaig Aghajanian
Haig Aghajanian
TKToru Kimura
Toru Kimura
JRJoel G. Rurik
Joel G. Rurik
AHAidan S. Hancock
Aidan S. Hancock
MLMichael S. Leibowitz
Michael S. Leibowitz
JEJonathan A. Epstein
Jonathan A. Epstein

9 December 2011 in Science
Verified
Journal Article
Closed access
PDF file
NTNORIFUMI TAKEDA
NORIFUMI TAKEDA
RJRajan Jain
Rajan Jain
MLMatthew R. LeBoeuf
Matthew R. LeBoeuf
QWQiaohong Wang
Qiaohong Wang
MLMin Min Lu
Min Min Lu
JEJonathan A. Epstein
Jonathan A. Epstein
Intestinal epithelial stem cell identity and location have been the subject of substantial research. Cells in the +4 niche are slow-cycling and label-retaining, whereas a different stem cell niche located at the crypt base is occupied by crypt base columnar (CBC) cells. CBCs are distinct from +4 cells, and the relationship between them is unknown, though both give rise to all intestinal epithelial lineages. We demonstrate that Hopx, an atypical homeobox protein, is a specific marker of +4 cells. Hopx-expressing cells give rise to CBCs and all mature intestinal epithelial lineages. Conversely, CBCs can give rise to +4 Hopx-positive cells. These findings demonstrate a bidirectional lineage relationship between active and quiescent stem cells in their niches.

26 July 2023 in Nature
Verified
Journal Article
Closed access
PDF file
DBDaniel J. Baker
Daniel J. Baker
ZAZoltan Arany
Zoltan Arany
JBJoseph A. Baur
Joseph A. Baur
JEJonathan A. Epstein
Jonathan A. Epstein
CJCarl H. June
Carl H. June

3 January 2006 in Circulation
Verified
Journal Article
Closed access
HKHae Jin Kee
Hae Jin Kee
ISIl Suk Sohn
Il Suk Sohn
KNKwang-Il Nam
Kwang-Il Nam
JPJong Eun Park
Jong Eun Park
YQYong Ri Qian
Yong Ri Qian
HKHyun Kook
Hyun Kook
Background— A number of distinct stress signaling pathways in myocardium cause cardiac hypertrophy and heart failure. Class II histone deacetylases (HDACs) antagonize several stress-induced pathways and hypertrophy. However, cardiac hypertrophy induced by transgenic overexpression of the homeodomain only protein, HOP, can be prevented by the nonspecific HDAC inhibitors trichostatin A and valproic acid, suggesting that alternate targets that oppose class II HDAC function might exist in myocardium. We tested the effects of several HDAC inhibitors, including a class I HDAC-selective inhibitor, SK-7041, on cardiac hypertrophy induced by angiotensin II (Ang II) treatment or aortic banding (AB). Methods and Results— Cardiac hypertrophy was induced by chronic infusion of Ang II or by AB in mice or rats and evaluated by determining the ratio of heart weight to body weight or to tibia length, cross-sectional area, or echocardiogram. Cardiac hypertrophy induced by Ang II or AB for 2 weeks was significantly reduced by simultaneous administration of trichostatin A, valproic acid, or SK-7041. Echocardiogram revealed that exaggerated left ventricular systolic dimensions were relieved by HDAC inhibitors. HDAC inhibitors partially reversed preestablished cardiac hypertrophy and improved survival of AB mice. The expressions of atrial natriuretic factor, α-tubulin, β-myosin heavy chain, and interstitial fibrosis were reduced by HDAC inhibition. Conclusions— These results suggest that the predominant effect of HDAC inhibition, mainly mediated by class I HDACs, is to prevent cardiac hypertrophy in response to a broad range of agonist and stretch stimuli.

1 March 2012 in Developmental Cell
Verified
Journal Article
Closed access
TKTamar C. Katz
Tamar C. Katz
MSManvendra Singh
Manvendra Singh
KDKarl Degenhardt
Karl Degenhardt
JRJosé Rivera-Feliciano
José Rivera-Feliciano
RJRandy L. Johnson
Randy L. Johnson
CTClifford J. Tabin
Clifford J. Tabin